(Deudextromethorphan hydrobromide + quinidine sulfate) is under clinical development by Avanir Pharmaceuticals and currently in the Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect (Deudextromethorphan hydrobromide + quinidine sulfate)’s likelihood of approval (LoA) and phase transition for Dementia Associated With Alzheimer’s Disease took place on 12 Sep 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their (Deudextromethorphan hydrobromide + quinidine sulfate) Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
(Deudextromethorphan hydrobromide + quinidine sulfate) overview
AVP-786 is under development for the treatment of residual schizophrenia symptoms, agitation associated with dementia of the Alzheimer's type. It is a next-generation Nuedexta. The drug candidate is administered as capsule through oral route. It consists of a combination of deuterium modified dextromethorphan hydrobromide and ultra-low dose quinidine sulfate. It is an NMDA receptor antagonist and acts as a non-competitive channel blocker. The drug candidate is developed using DCE Platform (Deuterated Chemical Entity Platform) technology that produces several deuterium-modified dextromethorphan compounds. It was under development for intermittent explosive disorder, levodopa-induced dyskinesia in Parkinson's disease, traumatic brain injury, treatment resistant major depressive disorder, disinhibition syndrome in patients with neurodegenerative disorders and neuropathic pain.
Avanir Pharmaceuticals overview
Avanir Pharmaceuticals (Avanir), a subsidiary of Otsuka Pharmaceutical Co Ltd. is a biopharmaceutical company that focuses on the research, development, and commercialization of medical and pharmaceutical treatments for central nervous system disorders. The company’s lead product include Nuedexta, a medication used for the treatment of pseudobulbar affect (PBA). The company’s pipeline product include AVP-786 intended for the treatment of agitation in Alzheimer’s disease, residual schizophrenia, intermittent explosive disorder, disinhibition in dementia and traumatic brain injury behavioral dysfunction, among others. Avanir is headquartered in Aliso Viejo, California, the US.
Quick View (Deudextromethorphan hydrobromide + quinidine sulfate) LOA Data
|Highest Development Stage|